Trial Condition(s):
Metastatic castration-resistant prostate cancer (mCRPC)
Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC)
Bayer Identifier:
18499
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
A retrospective secondary data analysis on clinical characteristics, treatment patterns and treatment costs, especially to identify Xofigo’s position in real life treatment pathway of CRPC patients.
Inclusion Criteria
: - All patients with a final diagnosis of mCRPC (=indication for the treatment with Xofigo) archived in ContraCare’s reimbursement database
Exclusion Criteria
No Exclusion Criteria Available
Trial Summary
Enrollment Goal
152
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No
Where to Participate
Locations
| Locations |
|---|
Trial Design
Analysis of Care for Patients with Castration-Resistant Prostate Cancer (CRPC) treated with Xofigo in Germany
Trial Type:
Observational
Intervention Type:
N/A
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
N/A
Primary Outcome
- Treatment duration of Xofigo and previous mCRPC therapies includingTimeframe:
- Sequence of mCRPC treatmentsTimeframe:
Secondary Outcome
- Time to treatment with XofigoTimeframe:
- Health insurance decision on the reimbursement of a Xofigo treatmentTimeframe:
- HospitalizationType of Intervention, Time point & duration of intervention, Costs of interventionTimeframe:
Additional Information
Copyright © Bayer
Powered by
